DiaMedica Therapeutics Inc.: insider trades · United States · SEC (Form 4)

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company listed on the Nasdaq Stock Market LLC under the ticker DMAC in the United States. For French-, Belgian- and Swiss-based investors, it is best understood as a development-stage biotech with a concentrated asset profile rather than a diversified commercial pharmaceutical company. The company’s strategy is focused on vascular diseases driven by impaired blood flow and endothelial dysfunction, with current clinical emphasis on preeclampsia, fetal growth restriction, and acute ischemic stroke. ([diamedica.com](https://www.diamedica.com/investors)) DiaMedica has a longer corporate history than its present market profile might suggest. The business traces back to 2000, and its current identity was shaped through corporate restructuring and a name change in 2016. Its headquarters are in Minneapolis, Minnesota, placing it in a well-established U.S. life-sciences hub. In market terms, DMAC remains a small-cap clinical biotech whose valuation case is tied to pipeline execution, clinical readouts, and continued access to capital markets to fund development. ([diamedica.com](https://www.diamedica.com/investors/financial-reports/sec-filings/content/0001437749-25-009703/0001437749-25-009703.pdf)) The company’s lead program is DM199, a recombinant form of human tissue kallikrein-1 (rhKLK1). DiaMedica describes DM199 as the first pharmaceutically active recombinant version of KLK1, designed to restore vascular function and improve blood flow while potentially reducing inflammation and oxidative stress. In preeclampsia and fetal growth restriction, the goal is to address the underlying pathophysiology rather than only symptoms. In acute ischemic stroke, the rationale is to enhance collateral perfusion and potentially broaden the treatment opportunity relative to current care pathways. ([diamedica.com](https://www.diamedica.com/company?utm_source=openai)) From a competitive standpoint, DiaMedica operates in a specialized but crowded biotech landscape. Its differentiation comes from the KLK1 biology and from the fact that kallikrein-based therapeutic concepts have historical precedent in Asia for vascular indications. That said, the company does not yet have a commercial product portfolio, so the investment thesis is highly binary and depends primarily on the quality of clinical evidence, enrollment progress, and regulatory traction. As with many clinical-stage names, the principal risks remain trial success, financing needs, and dilution. ([diamedica.com](https://www.diamedica.com/investors/press-releases/detail/1723/diamedica-therapeutics-reports-full-year-2025-financial)) Recent company updates reinforce that clinical development remains the central value driver. In 2025 DiaMedica disclosed interim Phase 2 preeclampsia results, and in 2026 it has continued to publish business updates and financial results, including commentary that the ReMEDy2 trial is continuing to enroll and expand globally. The company has also been active on the conference circuit in 2026, which is consistent with a small-cap biotech seeking broader institutional awareness. For investors monitoring SEC Form 4 insider transactions, DMAC should therefore be viewed as a research-driven Nasdaq issuer in the United States where insider activity, clinical milestones, and trial data can all have material impact on sentiment. ([diamedica.com](https://www.diamedica.com/))